Divi's Laboratories (DIVISLAB) Hisse Özeti
Divi's Laboratories Limited, Hindistan, Kuzey Amerika, Asya, Avrupa ve uluslararası alanda jenerik aktif farmasötik bileşenlerin (API'ler), ara ürünlerin ve nutrasötiklerin üretimi ve satışı ile ilgilenmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 0/6 |
| Gelecekteki Büyüme | 3/6 |
| Geçmiş Performans | 4/6 |
| Finansal Sağlık | 5/6 |
| Temettüler | 4/6 |
DIVISLAB Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Divi's Laboratories Limited Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | ₹6,887.00 |
| 52 Haftanın En Yüksek Seviyesi | ₹7,071.50 |
| 52 Haftanın En Düşük Seviyesi | ₹5,636.50 |
| Beta | 0.22 |
| 1 Aylık Değişim | 9.57% |
| 3 Aylık Değişim | 9.47% |
| 1 Yıllık Değişim | 6.23% |
| 3 Yıllık Değişim | 95.99% |
| 5 Yıllık Değişim | 67.15% |
| Halka arzdan bu yana değişim | 78,050.35% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • May 04
DIVISLAB: Elevated Future P/E Will Remain A Key Overvaluation Risk
Analysts have trimmed their price target on Divi's Laboratories slightly from ₹5,140 to about ₹5,133, reflecting updated assumptions around discount rates, revenue growth, profit margin, and future P/E expectations. Valuation Changes Fair Value: Trimmed slightly from ₹5,140.00 to about ₹5,133.17 per share.
Anlatı Güncellemesi • Apr 20
DIVISLAB: Upcoming Board Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target for Divi's Laboratories slightly, with fair value now seen around ₹8,620 versus about ₹8,554 earlier, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled on Feb 11, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).Anlatı Güncellemesi • Apr 05
DIVISLAB: Elevated Future P/E Will Persist Despite Unchanged Fair Value Estimate
Analysts have maintained Divi's Laboratories' fair value estimate at ₹5,140 per share, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together guide the latest price target narrative. What's in the News Board meeting scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).
Anlatı Güncellemesi • Mar 22
DIVISLAB: Upcoming Board Review And Fair Value Update Signal Constructive Outlook
Analysts have made a small upward adjustment to the fair value estimate for Divi's Laboratories to around ₹6,875, reflecting slightly updated assumptions on the discount rate, revenue growth, profit margins and future P/E. What's in the News Board meeting scheduled on February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Anlatı Güncellemesi • Mar 08
DIVISLAB: Rich Future P/E Will Persist Despite Softer Outlook After Results
Analysts have trimmed their price target on Divi's Laboratories from ₹5,290 to ₹5,140, reflecting updated assumptions around a slightly lower revenue growth outlook, a marginally higher profit margin, a modestly reduced future P/E multiple, and an adjusted discount rate. What's in the News A board meeting is scheduled for February 11, 2026 to review and approve unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Key Developments).Recent updates
Anlatı Güncellemesi • May 04
DIVISLAB: Elevated Future P/E Will Remain A Key Overvaluation Risk
Analysts have trimmed their price target on Divi's Laboratories slightly from ₹5,140 to about ₹5,133, reflecting updated assumptions around discount rates, revenue growth, profit margin, and future P/E expectations. Valuation Changes Fair Value: Trimmed slightly from ₹5,140.00 to about ₹5,133.17 per share.Anlatı Güncellemesi • Apr 20
DIVISLAB: Upcoming Board Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target for Divi's Laboratories slightly, with fair value now seen around ₹8,620 versus about ₹8,554 earlier, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled on Feb 11, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).Anlatı Güncellemesi • Apr 05
DIVISLAB: Elevated Future P/E Will Persist Despite Unchanged Fair Value Estimate
Analysts have maintained Divi's Laboratories' fair value estimate at ₹5,140 per share, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together guide the latest price target narrative. What's in the News Board meeting scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Anlatı Güncellemesi • Mar 22
DIVISLAB: Upcoming Board Review And Fair Value Update Signal Constructive Outlook
Analysts have made a small upward adjustment to the fair value estimate for Divi's Laboratories to around ₹6,875, reflecting slightly updated assumptions on the discount rate, revenue growth, profit margins and future P/E. What's in the News Board meeting scheduled on February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Anlatı Güncellemesi • Mar 08
DIVISLAB: Rich Future P/E Will Persist Despite Softer Outlook After Results
Analysts have trimmed their price target on Divi's Laboratories from ₹5,290 to ₹5,140, reflecting updated assumptions around a slightly lower revenue growth outlook, a marginally higher profit margin, a modestly reduced future P/E multiple, and an adjusted discount rate. What's in the News A board meeting is scheduled for February 11, 2026 to review and approve unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Key Developments).Anlatı Güncellemesi • Feb 22
DIVISLAB: Upcoming Results Review Will Shape Balanced Long Term Outlook
Narrative Update on Divi's Laboratories The analyst price target for Divi's Laboratories has been adjusted slightly higher from about ₹6,823 to roughly ₹6,870, with analysts pointing to small refinements in assumptions around discount rate, revenue growth, profit margin and future P/E as the drivers of this change. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Anlatı Güncellemesi • Feb 07
DIVISLAB: Upcoming Results Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target on Divi's Laboratories slightly to ₹6,823 from about ₹6,785, citing refreshed assumptions around discount rates, revenue growth, profit margin and future P/E that remain broadly in line with prior views. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Anlatı Güncellemesi • Jan 24
DIVISLAB: Management Changes And Rich Future P/E Will Sustain Excessive Optimism
Analysts now cite slightly higher assumptions on growth, profitability and future P/E in their models for Divi's Laboratories, which feeds into an updated fair value estimate of ₹5,290, compared with the previous ₹5,035.89. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Anlatı Güncellemesi • Jan 10
DIVISLAB: Upcoming Board Review And Management Changes Will Support Bullish Outlook
Analysts have raised their price target for Divi's Laboratories from ₹7,750 to about ₹8,554, citing updated assumptions related to revenue growth, profit margins and future P/E levels in their models. What's in the News Board meeting scheduled on Nov 07, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025 (company filing).Analiz Makalesi • Dec 30
Earnings Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)
Divi's Laboratories Limited's ( NSE:DIVISLAB ) price-to-earnings (or "P/E") ratio of 68.3x might make it look like a...Anlatı Güncellemesi • Dec 25
DIVISLAB: Rising Profitability Expectations Will Mask Moderating Revenue And Justify Excessive Optimism
Analysts have raised their price target for Divi's Laboratories from ₹4,756 to ₹5,036, citing expectations of stronger profitability and a slightly richer future valuation multiple, despite moderating revenue growth assumptions. What's in the News Board meeting scheduled for November 7, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Anlatı Güncellemesi • Dec 11
DIVISLAB: Upcoming Board Meeting And Leadership Review Will Shape Fair Outlook
Analysts have nudged their price target for Divi's Laboratories slightly higher, reflecting marginal improvements in discount rate assumptions and long term growth expectations that together support a fair value estimate of ₹6,785.10 per share. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 IST to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Analiz Makalesi • Dec 09
Divi's Laboratories (NSE:DIVISLAB) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Anlatı Güncellemesi • Nov 27
DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have raised their fair value estimate for Divi's Laboratories from ₹6,433 to ₹6,785, citing modest improvements in revenue growth and profit margin expectations. What's in the News A board meeting is scheduled for November 7, 2025, at 10:30 IST to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments).Analiz Makalesi • Nov 15
Investors Shouldn't Be Too Comfortable With Divi's Laboratories' (NSE:DIVISLAB) Earnings
Despite posting some strong earnings, the market for Divi's Laboratories Limited's ( NSE:DIVISLAB ) stock hasn't moved...Analiz Makalesi • Nov 11
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Divi's Laboratories Limited ( NSE:DIVISLAB ) just released its latest interim results and things are looking bullish...Anlatı Güncellemesi • Nov 08
DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have modestly increased their price target for Divi's Laboratories from ₹6,363 to ₹6,433, citing slight improvements in projected revenue growth and profit margins as the underlying factors. What's in the News Upcoming Board Meeting scheduled for November 7, 2025, at 10:30 AM IST.Analiz Makalesi • Sep 06
Divi's Laboratories Limited's (NSE:DIVISLAB) Share Price Could Signal Some Risk
With a price-to-earnings (or "P/E") ratio of 69.2x Divi's Laboratories Limited ( NSE:DIVISLAB ) may be sending very...Anlatı Güncellemesi • Sep 05
Custom Synthesis And Capacity Expansion Will Unlock Global Demand
With both the consensus price target and future P/E ratio for Divi's Laboratories remaining virtually unchanged, analysts signal stable valuation expectations, resulting in a steady fair value assessment at ₹6363. What's in the News Board meeting scheduled to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2025.Analiz Makalesi • Aug 10
Divi's Laboratories Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NSEI:DIVISLAB 1 Year Share Price vs Fair Value Explore Divi's Laboratories's Fair Values from the Community and select...Analiz Makalesi • Aug 05
Most Shareholders Will Probably Agree With Divi's Laboratories Limited's (NSE:DIVISLAB) CEO Compensation
Key Insights Divi's Laboratories' Annual General Meeting to take place on 11th of August CEO Kiran Divi's total...Analiz Makalesi • Jul 17
Here's What Analysts Are Forecasting For Divi's Laboratories Limited (NSE:DIVISLAB) After Its Yearly Results
Divi's Laboratories Limited ( NSE:DIVISLAB ) shareholders are probably feeling a little disappointed, since its shares...
Yeni Anlatı • Nov 10
Tactical Expansions And Innovation Could Offset Generic Pricing Pressures And Boost Profitability
Strategic investments in peptide synthesis and greenfield expansion enhance future revenue potential through capacity and product line growth.Hissedar Getirileri
| DIVISLAB | IN Life Sciences | IN Pazar | |
|---|---|---|---|
| 7D | 1.9% | -0.4% | -0.2% |
| 1Y | 6.2% | 3.3% | 0.02% |
Getiri vs. Endüstri: DIVISLAB geçen yıl % 3.3 oranında getiri sağlayan Indian Life Sciences sektörünü aştı.
Getiri vs Piyasa: DIVISLAB geçen yıl % 0 oranında getiri sağlayan Indian Piyasasını aştı.
Fiyat Oynaklığı
| DIVISLAB volatility | |
|---|---|
| DIVISLAB Average Weekly Movement | 2.8% |
| Life Sciences Industry Average Movement | 6.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.8% |
İstikrarlı Hisse Senedi Fiyatı: DIVISLAB son 3 ayda Indian piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: DIVISLAB 'nin haftalık oynaklığı ( 3% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1990 | 10,542 | Kiran Divi | www.divislabs.com |
Divi's Laboratories Limited, Hindistan, Kuzey Amerika, Asya, Avrupa ve uluslararası alanda jenerik aktif farmasötik bileşenlerin (API'ler), ara ürünlerin ve nutrasötiklerin üretimi ve satışı ile ilgilenmektedir. Şirket ayrıca API'lerin ve ara ürünlerin özel sentez fason üretim hizmetlerini üstlenmekte ve beta karoten, astaksantin, likopen ve kantaksantin gibi bir dizi karotenoidin yanı sıra lutein dahil olmak üzere diğer bitmiş formları ve vitaminleri gıda, besin takviyesi ve yem üreticileri endüstrilerine tedarik etmektedir. Ayrıca ürünlerini ihraç etmektedir.
Divi's Laboratories Limited Temel Bilgiler Özeti
| DIVISLAB temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | ₹1.82t |
| Kazançlar(TTM) | ₹24.79b |
| Gelir(TTM) | ₹103.14b |
73.8x
F/K Oranı17.7x
P/S OranıDIVISLAB aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| DIVISLAB gelir tablosu (TTM) | |
|---|---|
| Gelir | ₹103.14b |
| Gelir Maliyeti | ₹39.55b |
| Brüt Kâr | ₹63.59b |
| Diğer Giderler | ₹38.80b |
| Kazançlar | ₹24.79b |
Son Raporlanan Kazançlar
Dec 31, 2025
Sonraki Kazanç Tarihi
May 23, 2026
| Hisse başına kazanç (EPS) | 93.38 |
| Brüt Marj | 61.65% |
| Net Kâr Marjı | 24.04% |
| Borç/Özkaynak Oranı | 0.6% |
DIVISLAB uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
0.4%
Mevcut Temettü Verimi36%
Ödeme OranıŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 15:34 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/03/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Divi's Laboratories Limited 57 Bu analistlerden 30, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| Nitin Bhasin | Ambit Capital |